IGF-1 LR3 | Luxbae Peptide Therapy

Home › Peptides › IGF-1 LR3
Long-Acting IGF-1 Analogue

IGF-1 LR3 Direct IGF-1

A long-acting analogue of insulin-like growth factor-1 with reduced IGFBP binding and ~80× longer half-life.

Book Free ConsultationCall 310.299.4444

What IGF-1 LR3 actually is

IGF-1 LR3 (Long R3 IGF-1) is an engineered analogue of insulin-like growth factor-1 with two modifications: a 13-amino-acid N-terminal extension and an arginine substitution at position 3. These changes give roughly 80–100× longer half-life than native IGF-1 and substantially reduced binding to IGFBP-3 — the major circulating IGF binding protein.1

Reduced IGFBP binding means more free, bioactive IGF-1 reaches tissue receptors. IGF-1 mediates many of growth hormone’s downstream effects — muscle protein synthesis, dermal collagen, joint and tendon repair.2 We use it when GHRH/GHRP protocols don’t raise IGF-1 adequately, or when direct IGF support is the priority.

At Luxbae, IGF-1 LR3 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Bioavailable IGF-1

Reduced IGFBP-3 binding plus extended half-life delivers more free IGF-1 to receptor sites for prolonged signaling.1

What the research shows

Muscle protein synthesis. IGF-1 drives anabolic signaling at the muscle protein synthesis pathway.2

Connective tissue. Tendon and ligament repair supported by IGF-1-driven matrix biology.3

Recovery. Faster subjective recovery from training and rehabilitation.

Side effects: Hypoglycemia (most important to monitor), injection-site reactions, water retention, joint stiffness.

FDA note: Not FDA-approved. Native IGF-1 (mecasermin/Increlex) is approved for primary IGF-1 deficiency in children. Adult LR3 use is compounded and investigational.

IGF-1 LR3 FAQ

Why LR3 instead of regular IGF-1?
Reduced IGFBP binding and ~80× longer half-life — more free IGF-1 reaches tissue.

Hypoglycemia risk?
Real. Always inject with a carbohydrate plan ready; we counsel carefully on monitoring.

References

  1. Tomas FM, Knowles SE, Owens PC, et al. IGF-I and more potent variants restore growth of diabetic rats. Biochem J. 1991;276(Pt 2):547-554.
  2. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-568.
  3. Provenzano PP, Alejandro-Osorio AL, et al. Fibroblast-mediated remodeling of damaged collagen. Matrix Biol. 2005.

Start your IGF-1 LR3 protocol at Luxbae

Call 310.299.4444Book Online
Medical disclaimer: This is educational information, not medical advice. IGF-1 LR3 is investigational and many uses are not FDA-approved; treatments at Luxbae are administered under medical supervision by Dr. Ernst von Schwarz. Individual results vary.
Scroll to Top